U.S. Stocks in Motion | Trex Bio (TRXB.US) Debuts on the U.S. Stock Market, Falls Over 1.3% After the Open

Zhito Finance APP has learned that on Friday, Trex Bio (TRXB.US) debuted in the U.S. stock market. As of press time, the stock fell more than 1.3% to $13.805. The IPO price was $14. TRex Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that can enhance the function of regulatory T cells (Tregs) in inflamed human tissues, with the goal of restoring immune balance and repairing barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform is able to map the function of Tregs in human skin, gut, and lung tissues, thereby identifying targets and validating them through proprietary in vitro Treg models and high-throughput functional assays.